Ceftolozan / Tazobactam (1) – Zerbaxa®

Ospital-acquired pneumonia, ventilator-associated pneumonia

Characteristics

Start date 15.03.2020
Resolution 17.09.2020
INN Ceftolozan/Tazobactam
Brand name Zerbaxa®
Pharm. company MSD SHARP & DOHME GMBH
G-BA Procedure ID D-523
ATC code J01DI54 Other cephalosporins and penems (J01DI)
DDD 3 g P
Therapeutic area Infectious diseases Antibiotikatherapie, Nosocomial pneumonia (HAP)
Reason for procedure not completed: discontinued – Reserve antibiotic
Regulatory status Reserve antibiotic

Associated procedures

Ceftolozan / Tazobactam (7) Zerbaxa® MSD SHARP & DOHME GMBH Infectious diseases Bacterial infections, multiple indications, < 18 years of age 40 100% additional benefit considered proven
Ceftolozan / Tazobactam (6) Zerbaxa® MSD Sharp & Dohme GmbH Infectious diseases Bacterial infections, multiple indications 2,600–6,600 100% additional benefit considered proven
Ceftolozan / Tazobactam (5) Zerbaxa® MSD Sharp & Dohme GmbH Infectious diseases Complicated intra-abdominal infections, acute pyelonephritis, complicated urinary tract infections, hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) n.d. n.d.
Ceftolozan / Tazobactam (1) Zerbaxa® MSD SHARP & DOHME GMBH Infectious diseases Ospital-acquired pneumonia, ventilator-associated pneumonia n.d. discontinued
Ceftolozan / Tazobactam (2) Zerbaxa® MSD SHARP & DOHME GMBH Infectious diseases Complicated intra-abdominal infections n.d. discontinued
Ceftolozan / Tazobactam (3) Zerbaxa® MSD SHARP & DOHME GMBH Infectious diseases Complicated urinary tract infections n.d. discontinued
Ceftolozan / Tazobactam (4) Zerbaxa® MSD SHARP & DOHME GMBH Infectious diseases Acute pyelonephritis n.d. discontinued


<< List of all resolutions